For patients with cancers harboring certain genetic defects, the first-in-class targeted therapy RO7589831, which targets the DNA repair enzyme Werner helicase, demonstrated early signals of efficacy and was generally well-tolerated, according to Phase I trial data reported by researchers at The University of Texas MD Anderson Cancer Center.
Covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
